Structure of the major degradant of ezetimibe.

In a recent contribution to this Journal Gajjar and Shah described the isolation and structure elucidation of the major alkaline degradant of ezetimibe, a lipid lowering agent [A.K. Gajjar, V.

[The medications from the viewpoint of the psychotic patients].

In this paper is given a short introduction to the functioning of the group therapy of psychotic patients at our unit; outlining also other aspects of their treatment (medication, hospitalisation, group therapy). By collecting examples from the reports of the group therapy we illustrate how the medicaments appear in the conversations. We analyse the given data from three different point of view: interactional, thematic and by the psychotic contents.

Glycine transporter 1 expression in the ventral respiratory group is restricted to protoplasmic astrocytes.

The lack of the glycine transporter 1 (GlyT1) leads to early postnatal death due to failure of respiratory network activity. Here we demonstrate a segregated expression of GlyT1 on different astroglial cell populations of the ventral respiratory group. In TgN(hGFAP-EGFP) mice a combined immunohistochemical and electrophysiological approach was used to define the cellular expression of GlyT1 in the respiratory network.

Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition.

The glycine transporter subtype 1 (GlyT1) is widely expressed in astroglial cells throughout the mammalian central nervous system and has been implicated in the regulation of N-methyl-D-aspartate (NMDA) receptor activity. Newborn mice deficient in GlyT1 are anatomically normal but show severe motor and respiratory deficits and die during the first postnatal day. In brainstem slices from GlyT1-deficient mice, in vitro respiratory activity is strikingly reduced but normalized by the glycine receptor (GlyR) antagonist strychnine.